Theracryf Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Huw Jones

Amministratore delegato

UK£302.9k

Compenso totale

Percentuale dello stipendio del CEO	71.0%
Mandato del CEO	4.1yrs
Proprietà del CEO	0.7%
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Huw Jones rispetto agli utili di Theracryf?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	UK£303k	UK£215k	-UK£3m
Dec 31 2023	n/a	n/a	-UK£3m
Sep 30 2023	n/a	n/a	-UK£3m
Jun 30 2023	n/a	n/a	-UK£4m
Mar 31 2023	UK£305k	UK£200k	-UK£4m
Dec 31 2022	n/a	n/a	-UK£4m
Sep 30 2022	n/a	n/a	-UK£3m
Jun 30 2022	n/a	n/a	-UK£3m
Mar 31 2022	UK£240k	UK£188k	-UK£3m
Dec 31 2021	n/a	n/a	-UK£3m
Sep 30 2021	n/a	n/a	-UK£2m
Jun 30 2021	n/a	n/a	-UK£3m
Mar 31 2021	UK£224k	UK£88k	-UK£3m

Compensazione vs Mercato: La retribuzione totale di Huw ($USD 383.99K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 479.80K ).

Compensazione vs guadagni: La retribuzione di Huw è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Huw Jones (65 yo)

4.1yrs

Mandato

UK£302,890

Compensazione

Dr. Huw Jones, BSc, Ph D., serves as Non-Executive Director of Ixaka Limited since August 2023. He serves as Chief Executive Officer at Theracryf Plc (formerly known as Evgen Pharma plc) since October 1, 2...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Huw Jones	CEO & Executive Director	4.1yrs	UK£302.89k	0.74% € 20.0k
Toni Haenninen	CFO & Director	1.2yrs	UK£385.25k	0.23% € 6.3k
Helen Kuhlman	Chief Business Officer	3.6yrs	Nessun dato	0.25% € 6.6k
Glen Clack	Chief Medical Officer	3.5yrs	Nessun dato	0.23% € 6.3k

3.5yrs

Durata media

Gestione esperta: Il team dirigenziale di 8EV è considerato esperto (durata media dell'incarico 3.5 anni).

Theracryf Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Theracryf Plc Announces Demise of Sue Foden, Chair

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Recent updates

Theracryf Plc to Report First Half, 2025 Results on Nov 28, 2024

Less than half of directors are independent

Theracryf Plc Announces Demise of Sue Foden, Chair

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

New major risk - Shareholder dilution

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

New major risk - Revenue and earnings growth

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media